Assessing developability early in the discovery process for novel biologics
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properties that...
Saved in:
Main Authors: | Monica L. Fernández-Quintero, Anne Ljungars, Franz Waibl, Victor Greiff, Jan Terje Andersen, Torleif T. Gjølberg, Timothy P. Jenkins, Bjørn Gunnar Voldborg, Lise Marie Grav, Sandeep Kumar, Guy Georges, Hubert Kettenberger, Klaus R. Liedl, Peter M. Tessier, John McCafferty, Andreas H. Laustsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2023.2171248 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
by: Kyle P. Martin, et al.
Published: (2023-12-01) -
Design of antibody variable fragments with reduced reactivity to preexisting anti-drug antibodies
by: Maria U. Johansson, et al.
Published: (2023-12-01) -
Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion
by: Yoshiyuki Arata, et al.
Published: (2023-12-01) -
Advances in Symbiotic Bioabsorbable Devices
by: Chang Zhu, et al.
Published: (2025-06-01) -
WHO Expert Committee on Drug Dependence : reports /
Published: (1978)